---
title: "Obefazimod (ABX464) in Ulcerative colitis: ABX464-906"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: ABX464-906. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Statistical analysis description, and 1 further heading. 12 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence/abx464-906"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: ABX464-906

<a id="heading-3.1.9"></a>

## 3.1.9 ABX464-906

<a id="heading-3.1.9.1"></a>

### 3.1.9.1 Objective

<a id="topic-3.1.9.1-1"></a>

#### Purpose stated in the EU register title

> “A Phase 1, 2-part, open-label, single-sequence study to investigate the effect of single and multiple doses of obefazimod on the pharmacokinetics of rosuvastatin in healthy male participants.”

Source: [EU Clinical Trials Information System 2023-509226-21-00](https://euclinicaltrials.eu/ctis-public/view/2023-509226-21-00)

<a id="heading-3.1.9.2"></a>

### 3.1.9.2 Location and Study Date

<a id="topic-3.1.9.2-1"></a>

#### Trial dates and status in the EU register

| Field | Register entry |
| --- | --- |
| Protocol code | “Protocol code: ABX464-906” |
| Location | “Locations France” |
| Start of trial | “Start of trial 13/06/2024” |
| End of trial | “End of trial 20/02/2025” |

Source: [EU Clinical Trials Information System 2023-509226-21-00](https://euclinicaltrials.eu/ctis-public/view/2023-509226-21-00)

<a id="topic-3.1.9.2-2"></a>

#### Trial site

> “Eurofins Optimed”
> “clinical pharmacology unit, 1 Rue Des Essarts, 38610, Gieres”

Source: [CTIS.eu 2023-509226-21-00](https://ctis.eu/trial/2023-509226-21-00)

<a id="heading-3.1.9.3"></a>

### 3.1.9.3 Study Design

<a id="topic-3.1.9.3-1"></a>

#### Phase 1, two-part, open-label, single-sequence design

> “A Phase 1, 2-part, open-label, single-sequence study”
> “Trial Phase Human Pharmacology (Phase I)- Other”

Source: [EU Clinical Trials Information System 2023-509226-21-00](https://euclinicaltrials.eu/ctis-public/view/2023-509226-21-00)

<a id="topic-3.1.9.3-2"></a>

#### Drug-drug interaction trials described in the Form 20-F

> “In addition, three Phase 1 clinical trials have been completed in 2025 to assess the tolerability and safety profile of obefazimod”
> “two drug-drug interaction trials, for the purposes of providing further information on any possible interactions of obefazimod with other drugs”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.9.4"></a>

### 3.1.9.4 Eligibility Criteria

<a id="topic-3.1.9.4-1"></a>

#### Participant type, age, and sex in the EU register

| Field | Register entry |
| --- | --- |
| Participants type | “Participants type Healthy volunteers” |
| Age range | “Age range 18-64 years” |
| Population named in the title | “healthy male participants” |

Source: [EU Clinical Trials Information System 2023-509226-21-00](https://euclinicaltrials.eu/ctis-public/view/2023-509226-21-00)

<a id="heading-3.1.9.5"></a>

### 3.1.9.5 Treatment

<a id="topic-3.1.9.5-1"></a>

#### Single and multiple doses of obefazimod with rosuvastatin

> “the effect of single and multiple doses of obefazimod on the pharmacokinetics of rosuvastatin”

Source: [EU Clinical Trials Information System 2023-509226-21-00](https://euclinicaltrials.eu/ctis-public/view/2023-509226-21-00)

<a id="topic-3.1.9.5-2"></a>

#### Investigational medicinal product details not yet public

> “Details of the investigational medicinal products, including ATC codes”

Source: [CTIS.eu 2023-509226-21-00](https://ctis.eu/trial/2023-509226-21-00)

<a id="heading-3.1.9.6"></a>

### 3.1.9.6 Study Outcomes

<a id="heading-3.1.9.6.1"></a>

#### 3.1.9.6.1 Rationale for Using Rosuvastatin Pharmacokinetics as the Study Endpoint

No evidence found.

<a id="heading-3.1.9.7"></a>

### 3.1.9.7 Statistical Analysis Description

<a id="heading-3.1.9.7.1"></a>

#### 3.1.9.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.9.7.1-1"></a>

##### Planned participants in the EU register

> “France: Ended. Planned participants: 24”

Source: [CTIS.eu 2023-509226-21-00](https://ctis.eu/trial/2023-509226-21-00)

<a id="topic-3.1.9.7.1-2"></a>

##### Enrollment in the two drug-drug interaction trials stated in the Form 20-F

> “for which we enrolled 24 and 36 healthy volunteers respectively”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.9.7.2"></a>

#### 3.1.9.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.9.8"></a>

### 3.1.9.8 Results

<a id="heading-3.1.9.8.1"></a>

#### 3.1.9.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.9.8.2"></a>

#### 3.1.9.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.9.8.3"></a>

#### 3.1.9.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.9.8.4"></a>

#### 3.1.9.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.9.8.5"></a>

#### 3.1.9.8.5 Safety Results

No evidence found.

<a id="heading-3.1.9.9"></a>

### 3.1.9.9 Study Limitations

<a id="topic-3.1.9.9-1"></a>

#### Summary

ABX464-906 has only an EU register record and a sentence in the Form 20-F, which does not name the trial by protocol number. The register gives the title, the dates (13 June 2024 to 20 February 2025), one site in France, and 24 planned healthy volunteers aged 18 to 64 years; the 20-F reports two drug-drug interaction trials with 24 and 36 enrolled healthy volunteers. The objectives, endpoints, doses, and eligibility criteria are not public, and the summary of results is deferred under the rules for category 1 trials until 20 August 2027. The register limits the population to healthy men. No pharmacokinetic or safety result has been published.

Source: [EU Clinical Trials Information System 2023-509226-21-00](https://euclinicaltrials.eu/ctis-public/view/2023-509226-21-00); [CTIS.eu 2023-509226-21-00](https://ctis.eu/trial/2023-509226-21-00); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.9.9-2"></a>

#### Results publication deferred in the EU register

> “Summary of the results: deferred: adult category 1 trial (mostly phase I), results to be published from 20 Aug 2027 (EMA/263067/2023).”
> “Protocol and documents: deferred: documents of adult category 1 trials (mostly phase I) are not public while the deferral applies, until 20 Aug 2027 (EMA/263067/2023).”

Source: [CTIS.eu 2023-509226-21-00](https://ctis.eu/trial/2023-509226-21-00)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
